

COMPANY RELEASE

Crafton Biotechnology Co., Ltd. Announces the Appointment of Chief Chemistry Officer

Nagoya, Japan | August 1, 2025

Crafton Biotechnology Co., Ltd. (Crafton), a privately held biotech based in Nagoya, Japan, is pleased to announce the appointment of Tadashi Umemoto, PhD as its Chief Chemistry Officer (CCO). Dr. Umemoto will lead the research team in advancing Crafton's mRNA medicine platform, leveraging the company's pioneering PureCap® technology and chemically synthesized mRNA platform, to drive its pipeline of mRNA therapeutics.

Dr. Umemoto joins Crafton with extensive experience in therapeutic nucleic acid discovery and leadership. He brings deep expertise in the chemistry of therapeutic nucleic acids, having previously served as CSO at Luxna Biotech, a company specializing in therapeutic oligonucleotides. He also has a strong track record in the discovery of nucleic acid and peptide therapeutics at Takeda Pharmaceutical. Dr. Umemoto's expertise will be instrumental in advancing Crafton's mission to transform the treatment landscape for diseases that have historically been difficult to address, powered by Crafton's best-in-class and first-in-class technology platforms.

"I am honored to join Crafton and collaborate with great members who share a common vision for the future of mRNA medicines. Crafton's technologies are not only to mRNA vaccines but also to a broad range of mRNA therapeutics targeting diseases with unmet medical needs. I am eager to contribute to the further development of Crafton's mRNA platform and to help tackle diseases that have long posed significant treatment challenges." said Dr. Umemoto.

"We are thrilled to have Dr. Umemoto on board Crafton at this critical juncture. His addition to our C-Suite will help us shape our strategy and growth going forward bringing Crafton to the next level," commented President and CEO Hayato Watanabe, CFA.

